A multicenter clinical trial evaluating chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for stiff person syndrome (SPS), a rare autoimmune neurologic disorder, has produced promising early results. The study, published November 9, 2026 in JAMA Neurology, found early evidence of substantial clinical improvement among participants treated with CAR-T cell therapy. Researchers say the findings warrant further investigation in larger studies. The open-access article is titled “Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome.”
Hibsago (Bepirovirsen), Antisense Oligo, Approved in US for Treatment of Chronic Hepatitis B (CHB)
—Approval based on phase III data showing unprecedented functional cure rates compared to standard of care
—Six-month treatment with option of self-administration after first dose
—CHB affects approximately 1.7 million people in the US



On October 20, 2026, GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg) levels ≤3000 IU/ml, as determined by an FDA-authorised test. Bepirovirsen is a first-in-class antisense oligonucleotide (ASO) and offers unprecedented functional cure rates compared to current standard of care. The approval was granted under FDA Priority Review and Breakthrough Therapy Designation, recognizing significant improvement of bepirovirsen and nucleos(t)ide analog therapy over existing standard of care.
Honoring Atul Butte: A Year of Remembrance and Recommitment to Changing the World Together
Through the voices of family, friends, colleagues, students, and collaborators, this reposted retrospective (https://bakarinstitute.ucsf.edu/news/honoring-atul-butte-year-remembrance-and-recommitment-changing-world-together) reflects on the first year after Dr. Atul Butte’s premature passing and the enduring impact of his life and work.
Few modern scientists and entrepreneurs have made as broad an impact – or bridged as many domains – as Atul Butte, MD, PhD (1969-2025). He connected computer science and medicine, academia and industry, research and patient care, helping pioneer the modern field of computational health. He demonstrated how health and medical data could be used in new ways to understand and treat disease. Under his leadership, UCSF and the University of California system became a global hub for artificial intelligence, biomedical data science, and precision medicine. In a 2022 holiday message to his team, Dr. Butte wrote, “I can’t wait to see how we change the world together,” reflecting his uniquely bold thinking and collaborative spirit. Now, one year after his passing following a 2.5-year battle with cancer, his colleagues are continuing to advance his vision with the same positive energy and sense of purpose.
Uncovering Rules for Aggressive Brain Tumors Could Lead to Better Treatments
Aggressive brain tumors follow predictable rules, not chaotic randomness, according to new research. This discovery could lead to new, much needed ways to treat glioblastoma tumors in the future.



Researchers at the Wellcome Sanger Institute, the European Molecular Biology Laboratory (EMBL), the German Cancer Research Center (DKFZ), the Cancer Research UK Cambridge Institute, the Francis Crick Institute, and their collaborators, have mapped over one million cells across glioblastoma tumors. This allowed them to discover that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients.
In this new study, published November 4, 2026 in Nature, the team was able to categorize cancer cells at different stages of their journey within the different environments in glioblastoma tumors. They looked at different time stages and used lab-grown mini tumors to mimic this development. The open-access article is titled “A Spatiotemporal Cancer Cell Trajectory Underlies Glioblastoma Heterogeneity.”
Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research
On November 6, 2026, Insilico Medicine, a clinical-stage generative AI drug discovery company, announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si, in collaboration with leading geroscience researcher David Sinclair from Harvard Medical School. Developed for the Grok Bot platform, PLSI is an open-source, multi-agent AI system designed to unify fragmented personal health records, track biological analysis, formulate personalized lifestyle interventions, predict and score post-intervention biomarker changes, as well as drive communal AI-powered geroscience research.
New Treatment May Cure Common Hormonal Cause of High Blood Pressure; Study Published in NEJM
A study led by Queen Mary University of London has found that a new treatment could offer a lasting cure for some people with a common hormonal cause of high blood pressure, even after they stop taking medication. The treatment, known as extended aldosterone synthase inhibition (EASI), involves taking a new class of drugs for 6-12 months to target excess production of the hormone aldosterone, a common cause of high blood pressure. Unlike conventional treatments that control blood pressure, the EASI-treatment appears to reverse its underlying cause, removing the need for lifelong medication. Until now, cure has required surgery to remove an entire adrenal gland. The study, published November 7, 2026 in the New England Journal of Medicine, followed 14 people treated at eight centers across the United States. Researchers found that the EASI-treatment led to sustained reversal of excess aldosterone production and partial or complete resolution of high blood pressure for up to two years after treatment ended. The article is titled “Hyperaldosteronism Remission After Extended Aldosterone Synthase Inhibition.”
Illumina Selected to Help Bring Precision Medicine into Everyday Healthcare in Singapore
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore’s healthcare system
On November 2, 2026, Illumina, Inc. (Nasdaq: ILMN) announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore’s National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare. The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore’s public healthcare system, and help healthcare become more tailored to individuals over time.
How AI Is Filling the Gaps in Women’s Health Research



Midway through a woman’s menstrual cycle, her body undergoes a dramatic shift—one big enough to show up on a wearable fitness tracker. Her resting heart rate climbs, her body temperature rises half a degree, and her sleep becomes more restless. Hidden in those trends are important clues about her health. But the data is often not clear cut; drinking a glass of wine, running a marathon, or coming down with a common cold can throw off the numbers. And some signals practically disappear when a woman changes her diet, is breastfeeding, or grows older. All that noise means finding concrete links between shifts during the menstrual cycle and health outcomes is incredibly difficult. Most studies handle this challenge by excluding anyone whose data doesn’t fit a clean, predictable pattern—effectively erasing huge groups of people from menstrual health research.
Genomics and Plant Biology, Unearthed at CSHL



The instructions of life are written in DNA. But they’re in code, and it’s one that scientists are still deciphering. Cold Spring Harbor Laboratory (CSHL) has been a hub of pioneering genetics research for more than a century. Today, CSHL scientists have a suite of powerful, cutting-edge tools for sequencing, analyzing, and making purposeful tweaks to genomes. They’re deploying these tools to unearth long-held secrets of how plants and animals use their genetic codes. Their research is changing the ways scientists think about how genetic information is passed to future generations, how genes interact with the environment, and how genomes evolve over time. Their findings are opening new opportunities to make agricultural systems more productive while improving our understanding of the genes that shape human health and disease. Rob Martienssen, Chair of CSHL’s Genomics and Plant Biology program, says Cold Spring Harbor scientists have a history of making outsized contributions to these fields, from the Nobel-winning discovery of jumping genes to the mapping of the first plant genomes. Over the years, most of their biggest breakthroughs have come from asking important questions about how organisms use their DNA. “What sets us apart is that we really look at very fundamental things,” Martienssen explains. “We are still trying to understand the genetic basis for life on Earth.”
Bridging RARE Awards Honor Three Rare Disease Leaders at Virginia Gala
The gala united the rare disease community across borders and highlighted efforts to help an estimated 300 million people worldwide living with a rare condition.
The Indo US Organization for Rare Diseases (IndoUSrare) and the India-based Global Organisation for Rare Diseases (GORD) Foundation honored Anish Bhatnagar, Sumathi Iyengar, and Kumarasamy Thangaraj with the 2026 Abbey Meyers Khushi Bridging RARE Awards at a gala in Virginia that brought together patients, advocates, researchers, clinicians, and policymakers from across the rare disease community. Bhatnagar is a physician and orphan drug developer, Iyengar is founder of the Wiskott-Aldrich Syndrome Foundation, and Thangaraj is a population geneticist at the CSIR-Centre for Cellular and Molecular Biology in India. They were recognized for contributions to rare disease treatment, patient advocacy, and genomic research. The annual event, held at George Mason University’s Hylton Performing Arts Center in Manassas, Virginia, drew more than 100 representatives of advocacy groups, academia, healthcare, biotechnology, government, and philanthropy. It united the rare disease community across borders and highlighted efforts to help an estimated 300 million people worldwide living with a rare condition.
